Clozapine to prevent violence in schizophrenia
3/7 Clozapine for the Prevention of Violence in Schizophrenia: A Randomized Clinical Trial
['FUNDING_R01'] · UNIV OF NORTH CAROLINA CHAPEL HILL · NIH-11134680
This project explores if a medication called clozapine can help reduce violent behavior in people living with schizophrenia.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIV OF NORTH CAROLINA CHAPEL HILL (nih funded) |
| Locations | 1 site (CHAPEL HILL, UNITED STATES) |
| Trial ID | NIH-11134680 on ClinicalTrials.gov |
What this research studies
While most people with psychosis are not dangerous, some individuals with psychotic disorders face an increased risk for violence, which can lead to worse outcomes and increased stigma. We are conducting a large, multi-site clinical comparison to see if clozapine, an existing antipsychotic medication, is better than usual care at preventing violent acts. Participants will be randomly assigned to receive either clozapine or their standard treatment for 24 weeks. Our aim is to provide clear evidence on clozapine's effectiveness in reducing violence for individuals with schizophrenia in community settings.
Who could benefit from this research
Good fit: Ideal candidates are individuals diagnosed with schizophrenia who are identified as being at high risk for violent behavior.
Not a fit: Patients who do not have schizophrenia or are not at risk for violent behavior would not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this could provide a proven treatment option to significantly reduce violent behavior in individuals with schizophrenia, improving their safety and quality of life.
How similar studies have performed: Previous smaller studies have suggested clozapine's potential, but this project is a large, randomized comparison designed to provide more definitive evidence in real-world settings.
Where this research is happening
CHAPEL HILL, UNITED STATES
- UNIV OF NORTH CAROLINA CHAPEL HILL — CHAPEL HILL, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: JARSKOG, LARS FREDRIK — UNIV OF NORTH CAROLINA CHAPEL HILL
- Study coordinator: JARSKOG, LARS FREDRIK
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.